CS32582 is a highly selective small molecule allosteric inhibitor of tyrosine kinase 2 (TYK2) independently developed by Chipscreen Biosciences. It specifically binds to the regulatory pseudokinase JH2 domain of TYK2, ensuring selective inhibition of TYK2 without inhibiting other family members like JAK1, JAK2, and JAK3 at therapeutic doses. This unique feature ensures both therapeutic efficacy and safety. The inhibition of TYK2 by CS32582 can effectively block downstream signaling pathways mediated by cytokines such as interleukin (IL)-23, IL-12, and type I interferon (IFN), thereby exerting therapeutic effects on autoimmune diseases such as psoriasis. In preclinical studies, CS32582 showed significant therapeutic effects in mouse models of psoriasis.

In October 2023, an application for clinical trials of CS32582 capsules in the treatment of psoriasis in China has been approved, and the phase I dose escalation of CS32582 is currently progressing as planned.